New obesity drugs are coming, including the 'triple agonist' Retatrutide (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of bodyweight (in patients with obesity) in less than a year: New obesity drugs are coming, including the 'triple agonist' Retatrutide (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of bodyweight (in patients with obesity) in less than a year: 25% in a year might be a little fast
VONISH 0.2 TABLET - Voglibose (0.2mg) VONISH M 0.3 TABLET - Voglibose (0.3mg)+Metformin (500mg) (Bi-Layered) VONISH-M 0.2TABLET - Voglibose (0.2mg)+Metformin (500mg) (Bi-Layered) TRYPSAL AP TABLET - Aceclofenac (100mg) + Paracetamol (325mg) + Trypsin Chymotrypsin (50000au) TRYPSAL FORTE TABLET - Trypsin Chymotrypsin (100000au) TRYPTINE-10 TABLET - Amitriptyline (10mg) TRYPTINE-25 TABLET - Amitriptyline (25mg) ZINADOX-750 TABLET - PYRAZINAMIDE 750MG TABLET ZINOTAL 50 TABLET - ZINC ACETATE 50MG TABLET TOL DT 10 TABLET - Domperodopne 10mg TOLIFAX 150MG TABLET - Tolperisone (150mg) TOLIFAX 450MG TABLET - Tolperisone (450mg) TOLIFAX D TABLET - Each Film Coated Tablet Contains : Tolperisone Hydrochloride 150 Mg , Diclofenac Potassium Ip 50 Mg , Excipients Q.s
In 2005, the FDA approved exenatide, which was marketed as Byetta to treat diabetes
Rees, A
